Publications

Our abstract has been accepted as a podium presentation at ISPOR Copenhagen 2019

Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019

OBJECTIVES : The National Institute of Health and Care Excellence (NICE) undertakes clinical and cost-effectiveness assessments of pharmaceutical products. Products assessed by NICE can be either recommended, recommended with restrictions (i.e. optimised) or not recommended. Oncology products may also be recommended for use within the cancer drugs fund (CDF). This study compares the outcomes for oncology and non-oncology appraisals conducted by NICE.

METHODS : NICE single technology appraisals (STAs) published between January 2017 and January 2019 were identified. For each appraisal, outcomes of draft appraisal consultation documents (ACDs) and final appraisal determinations (FADs) were extracted. Outcomes of oncology and non-oncology appraisals were then analysed.

RESULTS : A total of 98 appraisals were identified, of which 66% and 34% were for oncology and non-oncology indications, respectively. ACDs were published […]

By |2019-08-09T11:50:02+01:00August 13th, 2019|News, Publications|0 Comments

Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?

Since 29 July 2016, the NICE appraisal process for oncology indications in England has been modified to allow one of three outcomes; recommended for routine use, not recommended, or recommended within the Cancer Drugs Fund (CDF) managed access scheme. This study investigates the outcomes of NICE appraisals for new cancer drugs assessed via the modified process.

Read our findings here…… (Is the new NICE appraisal process too positive?)

By |2018-10-19T15:05:25+01:00October 19th, 2018|Publications|0 Comments

ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US

Is there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if so, are any differences are solely driven by drug costs.

Read our findings here ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US

By |2018-06-08T12:34:52+01:00May 28th, 2018|Publications|0 Comments

What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

Remap Consulting recent analysis: “What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?” was presented at ISPOR’s 20th Annual European Congress in Glasgow.

In April 2016, NICE modified the Cancer Drugs Fund (CDF) appraisal process in England, to review all new oncology indications and publish final guidance within 90 days of marketing authorisation. Additionally, 14 existing legacy indications from the previous CDF had not undergone a NICE assessment and required review.

The new CDF has a fixed budget of £340m and treatments appraised under this process may; be recommended for routine use by NHS England; be retained in the CDF to gather additional evidence; not be recommended. In some cases, positive recommendations may be subject to confidential patient access schemes or restricted to specific patient populations.

This study investigates NICE evaluations of new cancer indications and of legacy CDF indications […]

By |2018-06-08T09:41:12+01:00November 13th, 2017|News, Publications|0 Comments